Related Articles
Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck
Small molecules in combination with conventional chemotherapeutic drugs: Light at the end of the tunnel?
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity
A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck